Today’s AI Top Pick: ZTS

7/23/2026 · Undervalued Emerging screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · Undervalued EmergingZTSBUY NOW8.8 / 107/23/2026

Zoetis is the cleanest asymmetric setup in the pool right now: elite fundamentals, an extreme washout that has already happened, unanimous multi-timeframe bullish forecasts, and a fresh positive product catalyst. Fundamentally it is the highest-quality name here — ROE 67.01%, profit margin 27.79%, operating margin 37.57%, gross margin 70.43%, fwdPe 10.07 (below the 15 screen ceiling), and analyst recom 1.95 with 44.9% target upside. The only fundamental blemish is PEG 1.34, but that is more than offset by the fact that the stock has been crushed (-41% YTD, -50.93% 1y, weekly drawdown -38.41% from 21-bar high, pos_in_21bar_range on the weekly of just 1.74%). This is a fallen quality-compounder, not a broken business. The tape confirms rather than fights the thesis. near_term_bullish = 1.0 with bullish_prob = 1.0, and every timeframe forecast is positive: 1h fc_short +6.36% / mid +17.34% / long +17.75%; 4h mid +27.72% / long +43.07%; 1d short +19.38% / mid +55.13% / long +66.13%; and the weekly is the standout at fc_short +23.62% / mid +104.7% / long +119.98%. That is genuine multi-timeframe agreement, and critically the 1h drawdown is only -1.93% while the 1d position in range is 50.55% — you are not chasing an extended candle, you are buying a base that just started to curl. The headline flow supports today as the entry rather than waiting. On 2026-07-22 Zoetis launched Portela (relfovetmab), a long-acting pet pain therapy for osteoarthritis, in Canada and the EU — a real product catalyst in its highest-margin franchise, not just noise. Compare this with the landmines in the pool: FUTU has a DOJ probe and class actions (2026-07-03), PEGA just missed Q2 and is trading lower (2026-07-22), CELH sits at 96.67% of its 1h range (chase risk), and ORLA/EQX/ITRG all show negative weekly forecasts. ZTS has none of that overhang. Why today, not later: the stock is compressed near the low of every meaningful range window, RSI is 40.53 (not oversold-panic, but well below stretched), and the daily forecast of +19.38% short-term suggests the base is about to resolve upward before the next earnings print. Waiting for a deeper pullback risks missing the initial rerating off a fresh catalyst on a name where the weekly forecast implies triple-digit upside over the intermediate horizon.

Entry zone

$73.50 – $75.50 (buy in thirds around spot $74.53; add on any dip toward the 1h low near $73)

Stop loss

$69.80 (below the recent weekly range low; roughly -6.3% from entry — invalidates the base)

First target

$84 – $86 (fills the 1d fc_short of +19% and coincides with prior supply)

Longer target

$100 – $115 (aligned with 1d fc_long +66% and analyst target upside 44.9%; the 1wk fc_mid/long +104%/+120% is the blue-sky case if the multiple normalizes)

Risks

PEG of 1.34 is the highest among top picks — if sales growth stays sluggish at 2.4% YoY, multiple expansion could stall
Weekly drawdown of -38.41% and perfYear of -50.93% mean the tape has been in a genuine downtrend; a failed breakout could retest lows
Debt/equity 2.86 is elevated for a healthcare name — rising rates or margin slippage would pressure the equity story
Livestock/companion-animal demand is macro-sensitive; consumer weakness could delay the earnings inflection the forecasts imply
The 1wk fc_long of +119.98% is an aggressive model output; single-timeframe outlier risk means position-size accordingly and trail stops as targets hit

Honorable mentions

TRMBCleanest 'not chasing' setup in the pool: pos_in_21bar_range 0–17% across all timeframes, near_term_bullish 1.0, all TFs positive with 1d fc_short +31.09% and fc_mid +49.39%, fwdPe 12.28, peg 0.80, analyst upside 62.2%. Earnings upcoming is a catalyst but also a risk, which knocks it below ZTS.

ADSKUnanimous multi-timeframe bullish (near_term 1.0), 1d fc_short +28.75% / mid +35.70%, ROE 50.4%, profit margin 19.46%, positive SeekingAlpha 'too cheap to ignore' piece 2026-07-18. Slightly higher fwdPe (14.33) and less drawdown-value than ZTS keep it at #3.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	ZTS	BUY NOW	8.8	Elite fundamentals, extreme washout, unanimous MTF forecasts, and a fresh product launch — highest-quality asymmetric entry today.
2	TRMB	BUY NOW	8.4	Pos_in_range 0–17% across all TFs, near_term 1.0, 1d fc_short +31%, fwdPe 12.28 — not chasing anything.
3	ADSK	BUY NOW	8.2	All timeframes green, 1d fc +28.75%, ROE 50%, positive analyst narrative — clean momentum name.
4	PDD	BUY NOW	8.0	fwdPe 6.77, peg 0.61, profit margin 21.9%, all TFs positive with 1d fc_short +26.98%.
5	ACM	BUY NOW	7.9	Low pos_in_range (0–21%), 1d fc_short +46.49%, fwdPe 10.04, contract-win newsflow.
6	HDB	BUY NOW	7.6	Deeply oversold (RSI 33, pos 0–20%), all TFs green, 'buy the dip' analyst call post NIM sell-off.
7	LOPE	BUY NOW	7.5	recom 1.00, pos 0–10%, all TFs positive with 1d fc_short +20.92%; only quibble is peg 1.19.
8	MORN	BUY NOW	7.3	near_term 1.0, 1wk fc_long +49.88%, fresh index-launch catalyst; slightly higher in range.
9	BILI	BUY NOW	7.1	All TFs positive, 1d fc_short +42%, 2Q preview reiterated Buy; pe 40 keeps it below top tier.
10	MNSO	BUY NOW	7.0	peg 0.17, fwdPe 7.85, near_term 0.8, 1d fc_short +53%, pos_in_range 0% on 1h.
11	EXLS	BUY NOW	6.9	near_term 1.0, all TFs green, board upgrade news, fwdPe 10.64 — steady compounder setup.
12	VNT	BUY PULLBACK	6.6	near_term 1.0 and fwdPe 8.13, but forecast magnitudes modest and 1d already at 80% of range.
13	ORCL	BUY PULLBACK	6.4	RSI 32 oversold with 1d fc_mid +39%, but 1wk forecasts negative and data-center cost narrative is a headwind.
14	NRDS	BUY PULLBACK	6.2	fwdPe 7.9, peg 0.26, all TFs positive, but near_term only 0.6 and micro-cap liquidity.
15	FIS	BUY PULLBACK	6.0	fwdPe 5.92 and 1wk fc_long +77%, but pos_in_range 3–19% with near-term softness on 1h/4h.
16	KKR	WAIT	5.8	Fundamentals fine, but 4h fc_short -4% and 1wk fc_long -1% show tape not confirming.
17	DCBO	WAIT	5.6	1h/4h forecasts turn negative despite strong weekly; substantial issuer bid supports but tape needs work.
18	GDDY	WAIT	5.5	fwdPe 9.96 and 1wk fc_long +49%, but D/E 16.22 and Q2 earnings this week make it a coin flip.
19	WK	WAIT	5.3	pe 225 and operMargin -0.26% mean any weakness gets punished; tape mixed.
20	WAY	WAIT	5.1	Earnings next week and 1h fc negative across horizons — no reason to front-run the print.
21	MLCO	WAIT	5.0	fwdPe 7.95 and constructive SA piece, but profit margin 4.33% and ROE null limit conviction.
22	FINV	WAIT	4.9	fwdPe 3.36 is optically cheap, but near_term only 0.4 and 1d recent bar -2.89%.
23	FRSH	AVOID	4.5	1h/4h forecasts negative, near_term 0.2, operMargin 1.79% — screen pass without tape support.
24	ORLA	AVOID	4.4	1wk fc_long -51% overrides positive daily; merger arb dynamics muddy the signal.
25	EQX	AVOID	4.3	1wk fc_long -32%, drawdown -43.91%; deal-close overhang keeps it capped.
26	ITRG	AVOID	4.1	1wk fc_long -36.58% and Zacks downgrade offset the Keybanc raise; too much divergence.
27	CELH	AVOID	3.9	1h at 96.67% of range = chase risk, pe 67.96, 4h/1wk near-term forecasts negative.
28	PGY	AVOID	3.5	1h/4h/1wk forecasts all negative; near-term bullish 0.8 rating not reflected in tape.
29	FUTU	AVOID	3.0	DOJ probe and class actions (07-03) — landmine that undercuts an otherwise strong forecast.
30	PEGA	AVOID	2.8	Q2 earnings miss (07-22) and shares trading lower — thesis just broke on the print.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord